Extracellular tumor-related mRNA in plasma of lymphoma patients and survival implications

PLoS ONE

Volumn 4, Issue 12, 2009, Pages

  Garcia, Vanesa ^a   Garcia, Jose Miguel ^a   Silva, Javier ^a   Martin, Paloma ^a   Peña, Cristina ^a   Dominguez, Gemma ^a   Diaz, Raquel ^a   Herrera, Mercedes ^a   Maximiano, Constanza ^a   Sabin, Pilar ^b   Rueda, Antonio ^c   Cruz, Miguel Angel ^d   Rodriguez, Jose ^b   Canales, Miguel Angel ^e   Bonilla, Felix ^a   Provencio, Mariano ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^d HOSPITAL VIRGEN DE LA SALUD   (Spain)

^e HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLIN D2; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; IMMUNOGLOBULIN HEAVY CHAIN; LACTATE DEHYDROGENASE; MESSENGER RNA; MYC PROTEIN; PREDNISONE; PROTEIN BCL 2; PROTEIN BCL 6; RITUXIMAB; VINBLASTINE; VINCRISTINE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLONAL VARIATION; CONTROLLED STUDY; DEATH; DRUG RESPONSE; FOLLICULAR LYMPHOMA; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME;

DISEASE-FREE SURVIVAL; EXTRACELLULAR SPACE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; NEOPLASTIC CELLS, CIRCULATING; RISK FACTORS; RNA, MESSENGER; RNA, NEOPLASM;

EID: 77949519057     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0008173     Document Type: Article

References (18)

1. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, et al. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346: 235-242.
2. Lossos IS, Morgensztern D (2006) Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol 24: 995-1007.
3. Lossos IS, Czerwinski DK, Alizadeh AA, Wechser MA, Tibshirani R, et al. (2004) Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 350: 1828-1837.
4. Garcia JM, Garcia V, Silva J, Peña C, Dominguez G, et al. (2006) Extracellular tumor DNA in plasma and overall survival in breast cancer patients. Genes Chromosomes Cancer 45: 692-701.
5. Garcia V, Garcia JM, Pena C, Silva J, Domínguez G, et al. (2008) Free circulating mRNA in plasma from breast cancer patients and clinical outcome. Cancer Lett 263: 312-320.
6. Gandhi MK, Lambley E, Burrows J, Dua U, Elliott S, et al. (2006) Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma. Clin Cancer Res 12: 460-464.
7. Frickhofen N, Muller E, Sandherr M, Binder T, Bangerter M, et al. (1997) Rearranged Ig heavy chain DNA is detectable in cell-free blood samples of patients with B-cell neoplasia. Blood 90: 4953-4960.
8. Dasi F, Lledo S, Garcia-Granero E, Ripoll R, Marugán M, et al. (2001) Real- time quantification in plasma of human telomerase reverse transcriptase (hTERT) mRNA: a simple blood test to monitor disease in cancer patients. Lab Invest 81: 767-769.
9. Garcia JM, Garcia V, Pena C, Domínguez G, Silva J, et al. (2008) Extracellular plasma RNA from colon cancer patients is confined in a vesicle-like structure and is mRNA-enriched. RNA 14: 1424-1432.
10. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, et al. (2007) Exosome- mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9: 654-659.
11. Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L, et al. (2008) Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 10: 1470-1476.
12. Van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, et al. (2003) Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4- CT98-3936. Leukemia 17: 2257-317.
13. Tibiletti MG, Martin V, Bernasconi B, Del Curto B, Pecciarini L, et al. (2009) BCL2, BCL6, MYC, MALT1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome. Hum Pathol 40: 645-652.
14. Shapiro B, Chakrabarty M, Cohn EM, Leon SA (1983) Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. Cancer 51: 2116-2120.
15. Silva JM, Rodriguez R, Garcia JM, Munoz C, Silva J, et al. (2002) Detection of epithelial tumour RNA in the plasma of colon cancer patients is associated with advanced stages and circulating tumour cells. Gut 50: 530-534.
16. Lossos IS, Morgensztern D (2006) Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol 24: 995-1007.
17. Seki R, Ohshima K, Fujisaki T, Uike N, Kawano F, et al. Cancer Sci 2009 100: 1842-1847.
18. A predictive model for aggressive Non-Hodgkin's lymphoma. The international Non-Hodgkin's lymphoma prognostic factors project. N Engl J Med 1993; 329: 987-994.